Adipotide (Adipotide (FTPP / Prohibitin-Targeting Peptide))
An experimental peptidomimetic designed to trigger targeted fat loss by cutting off the blood supply to white adipose tissue. It remains preclinical and is frequently searched by biohackers alongside other fat-loss peptides, but carries notable safety concerns.
How it works
A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed.
Key facts
- Molecular weight: ~2.6 kDa
- Half-life: Short (hours)
- Bioavailability: Subcutaneous injection
- Storage: Lyophilized: -20°C. Reconstituted: 2-8°C, use quickly.
Dosing overview
- Typical dose: Not established for human use
- Frequency: Research protocols only
- Duration: Short experimental courses
- Route: Subcutaneous injection
Protocol notes
- No validated human dosing exists; all human protocols are experimental and unapproved.
- Animal studies used weight-based dosing over short courses (weeks).
- Kidney monitoring was required in primate studies due to renal effects.
Reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
Possible side effects
- Kidney toxicity (dose-dependent)
- Dehydration
- Injection site reactions
- Unknown long-term human safety
- No approved human use
Research
- Adipotide induces weight loss in obese primates (2011): Produced significant fat loss and improved insulin resistance in obese rhesus monkeys, but with reversible kidney effects.
- Prohibitin-targeting vascular ablation of fat (2004): Demonstrated the proof of concept that ablating adipose vasculature causes rapid fat resorption in mice.
Compare Adipotide
Research and educational reference only. Not medical advice.